P-240 - Did the change of mRNA copy numbers in peripheral blood influence their relationship with colorectal cancer patients prognosis?

Date 04 July 2015
Event WorldGI 2015
Session Posters
Topics Colon Cancer
Rectal Cancer
Translational Research
Presenter Y. Liu
Citation Annals of Oncology (2015) 26 (suppl_4): 1-100. 10.1093/annonc/mdv233
Authors Y. Liu1, J. Feng2, J. Qian1, Y. Zhu1, H. Ju2, D. Li1
  • 1Charite-Universitätsmedizin, Berlin/DE
  • 2Zhejiang Cancer Hospital, Hangzhou/CN

Abstract

Introduction

The detection of circulating tumor cells (CTCs) in peripheral blood of colorectal cancer (CRC) patients was the important method for detecting micrometastases. The mRNA levels in peripheral blood reflect different CTCs burden of CRC patients and become the better factors for predicting patients' clinical outcome. But the positive mRNA levels in different articles were changed from above 0 copy to above 1000 copies. The objective of our study was to investigate the relationship of different mRNA copies of CTCs in peripheral blood with the prognosis in CRC patients without distant organ metastases.

Methods

The GCCmRNA and CK20mRNA levels in peripheral blood of 160 CRC patients without distant organ metastasis were detected by quantitative RT-PCR. The associations of different mRNA levels (from 0 to 10000 copy numbers) with five years disease-free survival (DFS) and overall survival (OS) rates were analyzed, in order to find the relationship of mRNA levels with patients prognosis.

Results

Kaplan-Meier curves showed that lower 5 years DFS rates were significantly associated with the presence of tumor emboli in vessels, the mesenteric root lymph node metastases, the lymph node metastases, the poor differentiation type, the high CA199 levels, the ulcerative pathological type and clinical stage III (p<0.05). While the lower 5 years OS rates were significantly associated with the presence of tumor emboli in vessels, the mesenteric root lymph node metastases, the lymph node metastases and the poor differentiation type (p<0.05). As to the different mRNA levels, DFS rates were significantly associated with nearly all levels GCCmRNA and CK20mRNA with stage II and low levels (200-900 copies) GCCmRNA with stage III; while OS rates were significantly associated with higher levels (>1500 copies) GCCmRNA with stage I, part of low levels GCCmRNA with stage II and stage III. As to the CK20mRNA, there were the same association with high levels (>900 copies) with stage I and nearly all levels with stage II. Multivariate statistic analyses showed a significant association between 1) OS and different GCC mRNA levels, CK20mRNA levels, tumor emboli in vessels, root lymph node metastases and differentiation types and 2) DFS and GCC mRNA levels, CA199 levels, emboli in vessels, root lymph node metastases, lymph node metastases and tumor location. All these clinical and pathology factors above were entered into the equation of prognosis and looked as risk factors except tumor location which was protect factor. Low mRNA copy numbers show less relationship with five years DFS and OS rates in patients from stage I to stage III, while the higher ones show significant relationship in patients with stage I and stage II.

Conclusion

The GCCmRNA and CK20mRNA in peripheral blood were prognostic relevance factors of CRC patients without distant organ metastases. The correctly choice of positive mRNA levels were useful in predicting distant organ metastasis and clinical outcome in those CRC patients.